A high NLR has been shown to be associated with a poor prognosis in several solid tumors including STS and might be helpful for patient stratification and individual risk assessment. The aims of this study were to confirm that higher NLR at baseline is associated with worse prognosis in STS and to evaluate if an early decline of NLR during treatment with pazopanib is associated with a more favorable prognosis.
The single-arm phase II EORTC 62043 and placebo-controlled phase III EORTC 62072 were both investigating the effect of pazopanib in patients with advanced STS. We evaluated NLR at baseline and 50 days later. Multivariate analyses on pazopanib-treated patients investigated the prognostic value on both Progression-Free Survival (PFS) and Overall Survival (OS) of NLR at baseline as well as the predictive value of changes in NLR from baseline to the 50-days landmark. Sensitivity analyses were conducted on the placebo-treated patients.
Among the 333 eligible patients treated with pazopanib, a NLR at baseline ≥3 was associated with shorter PFS and OS in comparison to NLR
In this study, limited by its retrospective design, the prognostic value of NLR at baseline was confirmed in advanced STS patients, irrespective of treatment. Changes in NLR during the first 50 days of treatment with pazopanib were not associated with patient outcome and can therefore not be used as an early marker for response.
Clinical trial identification
Legal entity responsible for the study
A. Le Cesne: Pfizer, Lilly, Amgen, Novartis, Pharmamar Honoraria, myself, compensated. P.G. Casali: Consultant/Advisory, Honoraria and Research funds (for the institution) from Amgen, Dompé, Bayer, Blueprint Medicines, Eisai, Eli Lilly, Daiichi Sankyo Pharma, Epizyme Inc., Merck SD, Merck Serono, Nektar Therapeutics, Novartis, Pfizer and PharmaMar. All other authors have declared no conflicts of interest.